Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

KIT exon 11 mutation

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

KIT exon 11 mutation	Melanoma	KIT exon 11 mutation	Melanoma	sunitinib Sensitive: A2 - Guideline sunitinib Sensitive : A2	sunitinib Sensitive: A2 - Guideline sunitinib Sensitive : A2
KIT exon 11 mutation	Melanoma	KIT exon 11 mutation	Melanoma	nilotinib Sensitive: A2 - Guideline nilotinib Sensitive : A2	nilotinib Sensitive: A2 - Guideline nilotinib Sensitive : A2
KIT exon 11 mutation	Gastric Cancer	KIT exon 11 mutation	Gastric Cancer	imatinib Sensitive: B - Late Trials imatinib Sensitive : B	imatinib Sensitive: B - Late Trials imatinib Sensitive : B
KIT exon 11 mutation	Gastrointestinal Stromal Tumor	KIT exon 11 mutation	Gastrointestinal Stromal Tumor	ripretinib Sensitive: B - Late Trials ripretinib Sensitive : B	ripretinib Sensitive: B - Late Trials ripretinib Sensitive : B
KIT exon 11 mutation	Gastrointestinal Stromal Tumor	KIT exon 11 mutation	Gastrointestinal Stromal Tumor	regorafenib Sensitive: B - Late Trials regorafenib Sensitive : B	regorafenib Sensitive: B - Late Trials regorafenib Sensitive : B
KIT exon 11 mutation	Gastrointestinal Stromal Tumor	KIT exon 11 mutation	Gastrointestinal Stromal Tumor	imatinib Sensitive: C2 – Inclusion Criteria imatinib Sensitive : C2	imatinib Sensitive: C2 – Inclusion Criteria imatinib Sensitive : C2
KIT exon 11 mutation	Gastrointestinal Stromal Tumor	KIT exon 11 mutation	Gastrointestinal Stromal Tumor	ponatinib Sensitive: C2 – Inclusion Criteria ponatinib Sensitive : C2	ponatinib Sensitive: C2 – Inclusion Criteria ponatinib Sensitive : C2
KIT exon 11 mutation	Melanoma	KIT exon 11 mutation	Melanoma	imatinib Sensitive: C3 – Early Trials imatinib Sensitive : C3	imatinib Sensitive: C3 – Early Trials imatinib Sensitive : C3
KIT exon 11 mutation	Gastrointestinal Stromal Tumor	KIT exon 11 mutation	Gastrointestinal Stromal Tumor	nilotinib Sensitive: C3 – Early Trials nilotinib Sensitive : C3	nilotinib Sensitive: C3 – Early Trials nilotinib Sensitive : C3
KIT exon 11 mutation	Gastrointestinal Stromal Tumor	KIT exon 11 mutation	Gastrointestinal Stromal Tumor	sunitinib Sensitive: C3 – Early Trials sunitinib Sensitive : C3	sunitinib Sensitive: C3 – Early Trials sunitinib Sensitive : C3
KIT exon 11 mutation	Gastrointestinal Stromal Tumor	KIT exon 11 mutation	Gastrointestinal Stromal Tumor	anlotinib Sensitive: C3 – Early Trials anlotinib Sensitive : C3	anlotinib Sensitive: C3 – Early Trials anlotinib Sensitive : C3
KIT exon 11 mutation	Gastrointestinal Stromal Tumor	KIT exon 11 mutation	Gastrointestinal Stromal Tumor	avapritinib Resistant: C4 – Case Studies avapritinib Resistant : C4	avapritinib Resistant: C4 – Case Studies avapritinib Resistant : C4
KIT exon 11 mutation	Melanoma	KIT exon 11 mutation	Melanoma	dasatinib Resistant: C4 – Case Studies dasatinib Resistant : C4	dasatinib Resistant: C4 – Case Studies dasatinib Resistant : C4